Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cinfa MD Discusses Biosimilar Products Approaching The Market

Executive Summary

At the 2017 BIO-Europe partnering meeting in Berlin, Germany, Ruediger Jankowsky managing director of Cinfa Biotech, talks about impending regulatory filings and decisions for its biosimilar drugs.

You may also be interested in...



Mundipharma Satisfies Appetite For Piece Of $4.5bn Pegfilgrastim Pie With Cinfa Biotech Buy

Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.

Mundipharma Satisfies Appetite For Piece Of $4.5bn Pegfilgrastim Pie With Cinfa Biotech Buy

Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.

TikoMed Seeks Partners For Regenerative Meds Pipeline

Tikomed CEO Adam Bruce talks to Scrip about the next steps for his company as it looks for partners to move forward with two clinical-stage programs.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC100106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel